XENE Xenon: Business Value to Revenue

Public company logo of xenon-pharma.com (XENE)

Geopolitical instability is limiting capital inflows into risky biotechnology, yet the success of Xenon Pharmaceuticals (XENE) depends solely on clinical trials. The GURU.Markets portal features a chart of the company's price-to-sales ratio, where the value remains around 0.00. This price action confirms the strategy of expanding the epilepsy drug portfolio prior to market entry following the final phase of trials.

Xenon Pharmaceuticals Inc (XENE) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

xenon-pharma.com - analytical breakdowns and key metrics (XENE)

- current quotes and average value forecast:
- company stock capitalization data:
- money and cash flow information:
Fundamental valuation:XENE - Xenon
Manufactured product of Xenon Pharmaceuticals

This indicator reflects the Enterprise Value of the entire business relative to revenue, excluding the impact of debt load to determine the real market valuation of assets. By analyzing changes in EV/Sales, an investor can assess the speculative gap in the valuation of Xenon Pharmaceuticals (XENE), where business stability depends directly on the success of XEN1101 clinical trials and the molecule's ability to obtain FDA certification.

Direct competitors

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple VKTX|EV/Sales Multiple supernus.com (SUPN)|Enterprise Value-to-Revenue Ratio Catalyst Pharmaceuticals, Inc. CPRX|DNLI (Denali Therapeutics Inc.) - Enterprise Value to Sales Volume|Harmony Corp - EV/Sales Multiple|BHVN: Enterprise Value-to-Revenue Ratio|AMLX: EV/Sales Multiple|TRVI: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio Praxis Medicines|Enterprise Value-to-Revenue Multiple Anavex AVXL|Enterprise Value-to-Revenue Ratio CeriBell Corp (CBLL)|Enterprise Value-to-Revenue Coefficient PRTA|EV/Sales Multiple ALEC (Alector)|Annexon (ANNX) - Enterprise Value-to-Revenue Multiple|OMER - Enterprise Value-to-Revenue Ratio|NGNE (Neurogene) - Company Value to Revenue Ratio|ACIU: EV/Sales Multiple|VYGR - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Neumora Therapeutics, Inc.|Company Value to Revenue Ratio SCLX (Scilex)|Company Value to Revenue TVGN (Tevogen Bio)|EV/Sales Multiple Alpha Cognition Inc (ACOG)|EV/Sales Multiple CGTX (cogrx.com)|Total Company Value-to-Revenue Ratio Inhibikase Pharma (IKT)|SAVA: Company Value to Revenue|Total Company Value-to-Revenue Ratio Assertio ASRT|COYA (coyatherapeutics.com) - Company Value to Revenue|Company Value to Revenue Ratio VTGN|OVID (Ovid Therapeutics) - EV/Sales Multiple|Acumen Pharmaceuticals, Inc (ABOS) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio CervoMed, Inc. (CRVO)|ATHE - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple CLNN (Clene Inc.)|Total Company Value-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Relmada Corp|ANVS (Annovis Bio, Inc.) - Company Value to Revenue|Grace Tx (GRCE) - EV/Sales Multiple|Company Value to Revenue AIFF|EV/Sales Multiple anewmeds.com|Enterprise Value-to-Revenue Ratio NeuroSense Therapeutics (NRSN)|RVPH (Reviva Pharmaceuticals Holdings) - Business Value to Revenue|MetaVia - Company Value to Revenue|NRXS: Company Value to Revenue Ratio|Helius Medical Technologies, Inc. - EV/Sales Multiple|PASG: Enterprise Value-to-Revenue Ratio|Neuphoria (NEUP) - Enterprise Value-to-Revenue Ratio|Minerva Neurosciences - Business Value to Revenue|ATHA (Athira Pharma, Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple addextherapeutics.com ADXN|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE